Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma
IC Nicholson, KA Lenton, DJ Little, T Decorso… - Molecular …, 1997 - Elsevier
IC Nicholson, KA Lenton, DJ Little, T Decorso, FT Lee, AM Scott, H Zola, AW Hohmann
Molecular immunology, 1997•ElsevierThe B cell specific antigen CD19 is a target for the immunotherapy of B lineage leukaemias
and lymphomas. We have engineered a single chain Fv (scFv) fragment from the mouse
hybridoma cell line FMC63 which produces monoclonal antibody specific for CD19. The
genes encoding the FMC63 heavy and light chain variable regions were amplified from
cDNA and a scFv was constructed by splice overlap extension PCR. Analysis of staining of
lymphoblastoid cell lines, peripheral blood lymphocytes and tonsil sections demonstrated …
and lymphomas. We have engineered a single chain Fv (scFv) fragment from the mouse
hybridoma cell line FMC63 which produces monoclonal antibody specific for CD19. The
genes encoding the FMC63 heavy and light chain variable regions were amplified from
cDNA and a scFv was constructed by splice overlap extension PCR. Analysis of staining of
lymphoblastoid cell lines, peripheral blood lymphocytes and tonsil sections demonstrated …
The B cell specific antigen CD19 is a target for the immunotherapy of B lineage leukaemias and lymphomas. We have engineered a single chain Fv (scFv) fragment from the mouse hybridoma cell line FMC63 which produces monoclonal antibody specific for CD19. The genes encoding the FMC63 heavy and light chain variable regions were amplified from cDNA and a scFv was constructed by splice overlap extension PCR. Analysis of staining of lymphoblastoid cell lines, peripheral blood lymphocytes and tonsil sections demonstrated that the monovalent scFv fragment has the same cellular specificity as the parent hybridoma antibody. Kinetic studies with radiolabelled material showed that the scFv binds target cells with a Ka of 2.3 × 10−9 for the parent antibody. This CD19 scFv will be used in experimental models to test its therapeutic efficacy and immunogenicity, with a view to application in the diagnosis and treatment of human B cell cancers.
Elsevier